Markers Can ID Aggressive Smoking-Associated Bladder Cancer

Researchers have identified bladder cancer markers that can predict which patients may have the most aggressive, fatal type of the disease. It was also discovered that smoking can affect the course of bladder cancer development, leading to more aggressive forms of the disease.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news

Related Links:

Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): C. Van Der Fels, S. Palthe, M.C. Van Den Heuvel, I.J. De Jong
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 10Author(s): R. Bientinesi, V. Di Paola, R. Manfredi, P. Bassi
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
ConclusionsA policy of selective histopathology after cholecystectomy is oncologically safe and reduces costs.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Condition:   Bladder Cancer Intervention:   Procedure: uretero ileal anastomosis in single trough Sponsor:   Ain Shams University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsPositive findings in abdominopelvic washing cytology is rare. The majority of the positive cases were from müllerian origins, with ovary and uterus as the most common sites. Endometrial adenocarcinoma, endometrioid type and ovarian high-grade serous carcinoma were the most common tumor types. Knowing prior history of malignancy, morphologic comparison with concurrent surgical cases, and performing ancillary studies are keys to improve diagnostic accuracy of abdominopelvic washings.
Source: Journal of the American Society of Cytopathology - Category: Cytology Source Type: research
ConclusionsPatient-related factors predicted 30  M whereas both patient-related and cancer-related factors predicted 30–90 M. This suggests that patient mix, i.e. patient- vs. cancer-related factors for 30 M and 30–90 M, should be taken into account if mortality rates are to be compared between hospitals.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 13 November 2019Source: Artificial Intelligence in MedicineAuthor(s): Ivan Lorencin, Nikola Anđelić, Josip Španjol, Zlatan CarAbstractIn this paper, the urinary bladder cancer diagnostic method which is based on Multi-Layer Perceptron and Laplacian edge detector is presented. The aim of this paper is to investigate the implementation possibility of a simpler method (Multi-Layer Perceptron) alongside commonly used methods, such as Deep Learning Convolutional Neural Networks, for the urinary bladder cancer detection. The dataset used for this research consisted of 1997 images of bl...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
Response classification after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma is based on the TNM stage at radical cystectomy. We recently showed that histopathologic tumor regression grades (TRGs) add prognostic information to TNM. Our aim was to validate the prognostic significance of TRG in muscle-invasive bladder cancer in a multicenter setting. We enrolled 389 patients who underwent cisplatin-based chemotherapy before radical cystectomy in 8 centers between 2010 and 2016. Median follow-up was 2.2 years. TRG was determined in radical cystectomy specimens by local pathologists. Central pathology review was...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
A combination of anthrax and a growth factor found on the surface of bladder cancer cells allowed Purdue University researchers to target and kill tumors with unprecedented speed.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
RAS protein activator like 2 (RASAL2) belongs to the RAS GTPase-activating protein family and plays an important role in several cancers, including ovarian cancer, nasopharyngeal carcinoma, malignant astrocytoma, renal cell carcinoma, bladder cancer, colorectal cancer, liver cancer, triple-negative breast cancer, lung adenocarcinoma, and pancreatic ductal adenocarcinoma. Traditionally, RASAL2 has been regarded as a tumor suppressor but recent studies have found that it is an oncogene in specific types of cancer, such as colorectal cancer, liver cancer, triple-negative breast cancer, triple-negative/estrogen receptor-negati...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Smokers